World Asset Management Inc Has $1.25 Million Position in Boston Scientific Co. (NYSE:BSX)

World Asset Management Inc cut its position in Boston Scientific Co. (NYSE:BSX) by 7.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,750 shares of the medical equipment provider’s stock after selling 2,257 shares during the quarter. World Asset Management Inc’s holdings in Boston Scientific were worth $1,247,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in BSX. FMR LLC grew its position in Boston Scientific by 19.8% in the second quarter. FMR LLC now owns 103,305,355 shares of the medical equipment provider’s stock valued at $4,417,338,000 after acquiring an additional 17,054,254 shares during the last quarter. Amundi acquired a new position in shares of Boston Scientific in the second quarter worth approximately $268,761,000. BlackRock Inc. boosted its stake in shares of Boston Scientific by 3.9% in the 3rd quarter. BlackRock Inc. now owns 122,400,261 shares of the medical equipment provider’s stock valued at $5,310,947,000 after purchasing an additional 4,557,618 shares during the last quarter. Deutsche Bank AG grew its holdings in Boston Scientific by 86.3% during the 3rd quarter. Deutsche Bank AG now owns 5,651,568 shares of the medical equipment provider’s stock worth $245,219,000 after acquiring an additional 2,618,098 shares during the period. Finally, Prudential Financial Inc. boosted its position in shares of Boston Scientific by 131.5% during the 2nd quarter. Prudential Financial Inc. now owns 3,497,858 shares of the medical equipment provider’s stock valued at $149,569,000 after purchasing an additional 1,986,615 shares in the last quarter. Institutional investors and hedge funds own 90.22% of the company’s stock.

Shares of NYSE:BSX opened at $44.86 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.15 and a current ratio of 1.55. The business has a 50-day simple moving average of $41.63 and a two-hundred day simple moving average of $43.15. Boston Scientific Co. has a fifty-two week low of $35.04 and a fifty-two week high of $46.28. The firm has a market cap of $63.93 billion, a price-to-earnings ratio of 61.45, a price-to-earnings-growth ratio of 2.54 and a beta of 0.89.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Tuesday, October 26th. The medical equipment provider reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.40 by $0.01. Boston Scientific had a net margin of 9.45% and a return on equity of 12.73%. The company had revenue of $2.93 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same quarter last year, the firm posted $0.37 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year. As a group, research analysts predict that Boston Scientific Co. will post 1.61 earnings per share for the current year.

Several analysts have recently commented on BSX shares. TheStreet upgraded Boston Scientific from a “c+” rating to a “b” rating in a research note on Thursday, January 6th. Truist Securities upped their price target on Boston Scientific from $52.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, December 21st. Royal Bank of Canada started coverage on shares of Boston Scientific in a research report on Thursday, December 9th. They issued an “outperform” rating and a $51.00 price objective for the company. Raymond James lowered their target price on Boston Scientific from $53.00 to $51.00 and set a “strong-buy” rating on the stock in a research note on Thursday, October 28th. Finally, Morgan Stanley reissued a “buy” rating and set a $53.00 target price on shares of Boston Scientific in a research report on Tuesday, September 21st. Three investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $49.72.

In related news, SVP Jodi Euerle Eddy sold 727 shares of Boston Scientific stock in a transaction dated Friday, October 22nd. The stock was sold at an average price of $45.00, for a total value of $32,715.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael F. Mahoney sold 201,042 shares of the firm’s stock in a transaction on Monday, November 1st. The stock was sold at an average price of $43.05, for a total value of $8,654,858.10. The disclosure for this sale can be found here. In the last ninety days, insiders sold 266,117 shares of company stock valued at $11,290,831. Corporate insiders own 0.71% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.

Recommended Story: Federal Reserve

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.